Normeg (Levetiracetam)

Levetiracetam, the active ingredient in Normeg, is an anticonvulsant presented as an oral tablet for oral use. It is prescribed to manage various seizure types in patients with epilepsy, including partial‑onset, generalized tonic‑clonic and myoclonic seizures.

GNH USA supplies Normeg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability, regulatory compliance, and dedicated technical support throughout the supply chain.

Levetiracetam is used in the management of epilepsy, targeting seizure activity across several seizure classifications.

- Partial-onset seizures: Reduces frequency and severity of focal seizures, improving daily functioning and quality of life. - Generalized tonic-clonic seizures: Helps control convulsive episodes, decreasing the risk of injury and hospitalization. - Myoclonic seizures: Diminishes sudden muscle jerks, aiding in the stabilization of motor control.

Levetiracetam may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness: Feeling unusually sleepy or fatigued. - Dizziness: Light‑headed sensation, especially when standing quickly. - Headache: Mild to moderate pain in the head region. - Irritability: Mood changes including increased agitation or anxiety. - Nausea: Stomach discomfort leading to an urge to vomit.

Serious or Rare Side Effects: - Severe allergic reaction: Rash, swelling, or difficulty breathing requiring immediate medical attention. - Mood disorders: Depression or suicidal thoughts that emerge during treatment. - Blood abnormalities: Low white blood cell or platelet counts observed in laboratory tests. - Multiorgan hypersensitivity: Rare syndrome with fever, rash, and organ involvement.

When prescribing levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: Adjust dose in patients with reduced kidney function. - Hepatic dysfunction: Monitor liver enzymes if underlying liver disease is present. - Psychiatric history: Observe for new or worsening depression, anxiety, or aggression. - Concomitant CNS depressants: Use caution when combined with other sedating agents. - Pregnancy and lactation: Evaluate risks versus benefits; limited data are available. - Store at ambient temperature: Keep below 25 °C in original packaging, protect from moisture.

Levetiracetam can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Carbamazepine: May reduce levetiracetam plasma levels, decreasing effectiveness. - Phenobarbital: Can lower drug concentration, potentially leading to breakthrough seizures.

Moderate Interactions (Monitor Closely): - Valproic acid: May increase levetiracetam levels, requiring monitoring for toxicity. - Alcohol: Enhances central nervous system depression, increasing drowsiness. - Other antiepileptics: Combined use may require dose adjustments based on clinical response.